Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7454199rdf:typepubmed:Citationlld:pubmed
pubmed-article:7454199lifeskim:mentionsumls-concept:C0003392lld:lifeskim
pubmed-article:7454199lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:7454199lifeskim:mentionsumls-concept:C0013162lld:lifeskim
pubmed-article:7454199lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:7454199lifeskim:mentionsumls-concept:C0332185lld:lifeskim
pubmed-article:7454199pubmed:dateCreated1981-3-17lld:pubmed
pubmed-article:7454199pubmed:abstractTextUsing four mouse tumor systems--leukemia L1210, i.m. mammary carcinoma 1142A, Lewis lung carcinoma, metastatic model of the mammary carcinoma 1142A--a combined treatment consisting of vincristine--cyclophosphamide--metrotrexate--5-fluorouracil is superior to a combined treatment with carminomycin--dibromodulcitol. The treatment with carminomycin and dibromodulcitol in each case alone causes therapeutic benefits being superior to a treatment with the combination carminomycin--dibromodulcitol. This result could be stated for all tumor systems used. Carminomycin showed the greatest effectivity against the leukemia L1210. A human tumor nude mouse system--ascitic mesothelioma 1503A--is presented which is suitable for chemotherapeutic experiments. First test results indicated an antineoplastic effectivity after daunoblastin treatment, but cyclophosphamide and carminomycin did not influence the life span.lld:pubmed
pubmed-article:7454199pubmed:languageenglld:pubmed
pubmed-article:7454199pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7454199pubmed:citationSubsetIMlld:pubmed
pubmed-article:7454199pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7454199pubmed:statusMEDLINElld:pubmed
pubmed-article:7454199pubmed:issn0030-2414lld:pubmed
pubmed-article:7454199pubmed:authorpubmed-author:ArnoldWWlld:pubmed
pubmed-article:7454199pubmed:authorpubmed-author:TannebergerSSlld:pubmed
pubmed-article:7454199pubmed:authorpubmed-author:NowakCClld:pubmed
pubmed-article:7454199pubmed:authorpubmed-author:NaundorfHHlld:pubmed
pubmed-article:7454199pubmed:issnTypePrintlld:pubmed
pubmed-article:7454199pubmed:volume37 Suppl 1lld:pubmed
pubmed-article:7454199pubmed:ownerNLMlld:pubmed
pubmed-article:7454199pubmed:authorsCompleteYlld:pubmed
pubmed-article:7454199pubmed:pagination34-41lld:pubmed
pubmed-article:7454199pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:meshHeadingpubmed-meshheading:7454199-...lld:pubmed
pubmed-article:7454199pubmed:year1980lld:pubmed
pubmed-article:7454199pubmed:articleTitleRecent results with clinically used antineoplastic drugs and drug combinations in vivo.lld:pubmed
pubmed-article:7454199pubmed:publicationTypeJournal Articlelld:pubmed